KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBITDA: 2009-2025

Historic EBITDA for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -$160.2 million.

  • Ionis Pharmaceuticals' EBITDA fell 7.75% to -$160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.0 million, marking a year-over-year increase of 24.93%. This contributed to the annual value of -$475.1 million for FY2024, which is 34.31% down from last year.
  • Ionis Pharmaceuticals' EBITDA amounted to -$160.2 million in Q3 2025, which was down 214.57% from $139.8 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' EBITDA peaked at $220.6 million during Q4 2021, and registered a low of -$208.0 million during Q4 2022.
  • For the 3-year period, Ionis Pharmaceuticals' EBITDA averaged around -$90.5 million, with its median value being -$114.1 million (2023).
  • In the last 5 years, Ionis Pharmaceuticals' EBITDA skyrocketed by 1,073.36% in 2021 and then plummeted by 1,710.21% in 2024.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' EBITDA stood at $220.6 million in 2021, then plummeted by 194.30% to -$208.0 million in 2022, then soared by 97.06% to -$6.1 million in 2023, then slumped by 1,710.21% to -$110.8 million in 2024, then declined by 7.75% to -$160.2 million in 2025.
  • Its EBITDA was -$160.2 million in Q3 2025, compared to $139.8 million in Q2 2025 and -$146.9 million in Q1 2025.